Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure

Journal of Infectious Diseases

Volumn 210, Issue 3, 2014, Pages 363-373

  Jose, Sophie ^a   Hamzah, Lisa ^b   Campbell, Lucy J ^b   Hill, Teresa ^a   Fisher, Martin ⁱ   Leen, Clifford ^j   Gilson, Richard ^c   Walsh, John ^d   Nelson, Mark ^e   Hay, Phillip ^f   Johnson, Margaret ^g   Chadwick, David ^k   Nitsch, Dorothea ^h   Jones, Rachael ^e   Sabin, Caroline A ^a   Post, Frank A ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ UK   (United Kingdom)

^j NHS LOTHIAN   (United Kingdom)

^k SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

EGFR; EGFR slopes; Highly active antiretroviral therapy; Kidney; Renal function; Tenofovir

Indexed keywords

TENOFOVIR DISOPROXIL; ATAZANAVIR; CREATININE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONVALESCENCE; DETERIORATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; REVERSAL REACTION; RISK ASSESSMENT; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ADOLESCENT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ETHNICITY; FOLLOW UP; GENDER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; UNITED KINGDOM; VIRUS LOAD;

EGFR; EGFR SLOPES; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; KIDNEY; RENAL FUNCTION; TENOFOVIR;

ADENINE; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROPORTIONAL HAZARDS MODELS; VIRAL LOAD;

EID: 84904334133     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu107     Document Type: Article

References (50)

1. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
2. EACS guidelines, 2012. Available at: http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6. 1-2edition.pdf. Accessed 24 June 2013.
3. Antiretroviral therapy for HIV infection in adults and adolescents, 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf. Accessed 24 June 2013.
4. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
5. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-40.
6. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-63.
7. Fux CA, Simcock M,Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007; 12:1165-73.
8. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 2009; 10:329-36.
9. Horberg M, Tang B, TownerW, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53:62-9.
10. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23:689-96.
11. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther 2009; 14:543-9.
12. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-75.
13. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-78.
14. Campbell LJ, Dew T, Salota R, et al. Urinary albumin and retinolbinding protein as markers of glomerular and tubular dysfunction in HIV infected patients. In: 12th European AIDS Conference/EACS, Cologne, Germany, 11-14 November 2009.
15. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 2011; 25:1603-9.
16. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331-3.
17. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004; 24:415-8.
18. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect 2005; 51:E61-5.
19. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 2009; 25:387-94.
20. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010; 55:78-81.
21. Yoshino M, Yagura H, Kushida H, et al. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation. J Infect Chemother 2012; 18:169-74.
22. Bonjoch A, Echeverria P, Perez-Alvarez N, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res 2012; 96:65-9.
23. Campbell LJ, Hamzah L, Post FA. Is tenofovir-related renal toxicity incompletely reversible? J Acquir Immune Defic Syndr 2011; 56:e95.
24. Fafin C, Pugliese P, Durant J, et al. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73m. Nephron Clin Pract 2012; 120:c205-14.
25. Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26:1907-15.
26. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-24.
27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-12.
28. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIVpositive patients. Nephrol Dial Transplant 2011; 27:2291-7.
29. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007; 24:811-5.
30. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001; 299:567-74.
31. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-87.
32. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48:e108-16.
33. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78:1171-7.
34. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43:278-83.
35. Fux C, Opravil M, Cavassini M, et al. Tenofovir and PI Use Are Associated with an Increased Prevalence of Proximal Renal Tubular Dysfunction in the Swiss HIV Cohort Study. In: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8-11 February 2009.
36. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567-75.
37. Dazo C, Fahey P, Puls RL, et al. Small but significant and nonprogressive decline in glomerular filtration rate is observed in therapy naïve HIV-positive subjects commencing ritonavir-boosted atazanavir (r/ATV), compared to either efavirenz (EFV) or zidovudine/abacavir (ZDV/ABC) all with tenofovir (TDF)/emtricitabine (FTC) after 48 weeks, a randomised controlled study. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, 27 Feb-2 March 2011.
38. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-23.
39. Biesecker G, Karimi S, Desjardins J, et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res 2003; 58:217-25.
40. Cooper RD,Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
41. Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis 2013; 56:567-75.
42. Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS 2011; 25:2149-55.
43. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10:482-7.
44. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46: 1271-81.
45. Makie T, Nagai S, Sasakawa A, Kawamura K, Kuwahara T. Predicting tenofovir concentration on the basis of renal factors determined by routine tests. Am J Ther 2007; 14:514-8.
46. Lepist E, Murray BP, Tong L, Roy A, Bannister R, Ray AS. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [abstract A1-1724]. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 17-20 September 2011.
47. Bandaranayake N, Ankrah-Tetteh T, Wijeratne S, Swaminathan R. Intra-individual variation in creatinine and cystatin C. Clinl Chem Lab Med 2007; 45:1237-9.
48. Larsson A, Akerstedt T, Hansson LO, Axelsson J. Circadian variability of cystatin C, creatinine, and glomerular filtration rate (GFR) in healthy men during normal sleep and after an acute shift of sleep. Chronobiol Int 2008; 25:1047-61.
49. Reinhard M, Erlandsen EJ, Randers E. Biological variation of cystatin C and creatinine. Scand J Clin Lab Invest 2009; 69:831-6.
50. Badrick T, Turner P. The Uncertainty of the eGFR. Indian J Clin Biochem 2013; 28:242-7.